Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063386 | 1.00 | PDE2A (0.32) | PDE2AAPLNRAGBL2 | |
| SCHEMBL588625 | 1.00 | PDE2A (0.32) | PDE2AAPLNRAGBL2 | |
| Hydrochloric Acid SCHEMBL1396011 | 0.98 | PDE2A (0.31) | PDE2A | |
| Hydrochloric Acid SCHEMBL3233623 | 0.98 | PDE2A (0.31) | PDE2A | |
| Hydrochloric Acid SCHEMBL456413 | 0.98 | PDE2A (0.31) | PDE2A | |
| Hydrochloric Acid SCHEMBL31146375 | 0.98 | PDE2A (0.31) | PDE2A | |
| SCHEMBL2737358 | 0.83 | AGBL2 (0.32) | AGBL2 | |
| SCHEMBL3229114 | 0.82 | DPP4 (0.32) | — | |
| SCHEMBL21725703 | 0.80 | S1PR3 (0.42) | — | |
| SCHEMBL17823722 | 0.80 | S1PR3 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4594307-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250154111-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| WO-2024073426-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-4175954-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2023-05-10 | — | — | EP | disclosed |
| CN-116057057-A | Conjugates of alpha 2-adrenoceptor subtype C (alpha-2C) antagonists and TASK1/3 channel blockers for the treatment of sleep apnea | 拜耳公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-114929694-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-110563717-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-109563085-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | disclosed |
| WO-2010020810-A1 | 2-(IMIDAZ0LYLAMIN0)-PYRIDINE DERIVATIVES AND THEIR USE AS JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2009150462-A1 | TRICYCLIC 2,4-DIAMIN0-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009150462-A1 | TRICYCLIC 2,4-DIAMIN0-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009016410-A2 | CHEMICAL COMPOUNDS 831 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016410-A2 | CHEMICAL COMPOUNDS 831 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| WO-2008132502-A1 | PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008117050-A1 | PYRAZOLYL-AMINO-SUBSTITUTED PYRAZINES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | WO | disclosed |
| EP-1899323-A2 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006123113-A2 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ABL1, FLT3, ERBB2 | PDE2A 1035/4885APLNR 3478/4885AGBL2 1426/4885 |
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | TNNT2, TNNI3, TNNC1 | PDE2A 281/4885APLNR 3128/4885AGBL2 4756/4885 |
| US-20250154111-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, SDHA | PDE2A 108/4885APLNR 4512/4885AGBL2 4582/4885 |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, SDHA | PDE2A 108/4885APLNR 4512/4885AGBL2 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.